The dipeptidyl peptidase-4 inhibitor-sitagliptin modulates calcium dysregulation, inflammation, and PPARs in hypertensive cardiomyocytes

International Journal of Cardiology

Volumn 168, Issue 6, 2013, Pages 5390-5395

  Lee, T I ^a,b   Kao, Y H ^a,b   Chen, Y C ^c   Huang, J H ^b   Hsu, M I ^b   Chen, Y J ^a,b  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

Calcium handling; Cardiomyocytes; DPP 4 inhibitor; Hypertension; Sitagliptin

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ANGIOTENSIN 2 RECEPTOR; INTERLEUKIN 6; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; POTASSIUM CHANNEL KV1.4; POTASSIUM CHANNEL KV11.1; POTASSIUM CHANNEL KV7.1; RYANODINE RECEPTOR; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SITAGLIPTIN; SODIUM CALCIUM EXCHANGE PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VOLTAGE DEPENDENT ANION CHANNEL; VOLTAGE GATED SODIUM CHANNEL;

ACTION POTENTIAL; ANIMAL CELL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARRHYTHMOGENESIS; ARTICLE; CALCIUM HOMEOSTASIS; CALCIUM METABOLISM; CARDIOVASCULAR INFLAMMATION; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ELECTROCARDIOGRAM; HEART MUSCLE CELL; HYPERTENSION; MICROELECTRODE; NONHUMAN; POTASSIUM CURRENT; PR INTERVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; QT PROLONGATION; RAT; SYSTOLIC BLOOD PRESSURE; UPREGULATION;

CALCIUM HANDLING; CARDIOMYOCYTES; DPP-4 INHIBITOR; HYPERTENSION; SITAGLIPTIN;

ACTION POTENTIALS; ANIMALS; BLOOD PRESSURE; CALCIUM; CARDIOTONIC AGENTS; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; ELECTROCARDIOGRAPHY; HEART VENTRICLES; HYPERTENSION; INFLAMMATION; INTERLEUKIN-6; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PPAR ALPHA; PPAR DELTA; PPAR GAMMA; PYRAZINES; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, IMMUNOLOGIC; TRIAZOLES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84887202275     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.08.051     Document Type: Article

References (36)

1. B. Ahren, J.J. Holst, H. Martensson, and B. Balkan Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice Eur J Pharmacol 404 2000 239 245
2. B. Balkan, L. Kwasnik, R. Miserendino, J.J. Holst, and X. Li Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats Diabetologia 42 1999 1324 1331
3. K. Ban, S. Hui, D.J. Drucker, and M. Husain Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin-based therapies J Am Soc Hypertens 3 2009 245 259
4. D.J. Drucker, and A.B. Goldfine Cardiovascular safety and diabetes drug development Lancet 377 2011 977 979
5. Q. Yang, and Y. Li Roles of PPARs on regulating myocardial energy and lipid homeostasis J Mol Med 85 2007 697 706
6. S. Lewington, R. Clarke, N. Qizilbash, R. Peto, and R. Collins Prospective studies C: age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies Lancet 360 2002 1903 1913
7. M.F. Allard, B.O. Schonekess, S.L. Henning, D.R. English, and G.D. Lopaschuk Contribution of oxidative metabolism and glycolysis to ATP production in hypertrophied hearts Am J Physiol 267 1994 H742 H750
8. M.E. Christe, and R.L. Rodgers Altered glucose and fatty acid oxidation in hearts of the spontaneously hypertensive rat J Mol Cell Cardiol 26 1994 1371 1375
9. M.J. Goikoetxea, J. Beaumont, and A. Gonzalez Altered cardiac expression of peroxisome proliferator-activated receptor-isoforms in patients with hypertensive heart disease Cardiovasc Res 69 2006 899 907
10. T.I. Lee, Y.H. Kao, Y.C. Chen, N.H. Pan, Y.K. Lin, and Y.J. Chen Cardiac peroxisome-proliferator-activated receptor expression in hypertension co-existing with diabetes Clin Sci (Lond) 121 2011 305 312
11. C.J. Lyon, R.E. Law, and W.A. Hsueh Minireview: adiposity, inflammation, and atherogenesis Endocrinology 144 2003 2195 2200
12. L. Sun, Y. Ke, and C.Y. Zhu Inflammatory reaction versus endogenous peroxisome proliferator-activated receptors expression, re-exploring secondary organ complications of spontaneously hypertensive rats Chin Med J (Engl) 121 2008 2305 2311
13. G.H. Fukumoto, S.T. Lamp, C. Motter, J.H. Bridge, A. Garfinkel, and J.I. Goldhaber Metabolic inhibition alters subcellular calcium release patterns in rat ventricular myocytes: implications for defective excitation-contraction coupling during cardiac ischemia and failure Circ Res 96 2005 551 557
14. 2 + release contributes to automaticity in cat atrial pacemaker cells J Physiol 524 Pt 2 2000 415 422
15. W.T. Clusin Mechanisms of calcium transient and action potential alternans in cardiac cells and tissues Am J Physiol Heart Circ Physiol 294 2008 H1 H10
16. T.I. Lee, Y.C. Chen, Y.H. Kao, F.C. Hsiao, Y.K. Lin, and Y.J. Chen Rosiglitazone induces arrhythmogenesis in diabetic hypertensive rats with calcium handling alteration Int J Cardiol 165 2013 299 307
17. J.P. Morrow, A. Katchman, and N.H. Son Mice with cardiac overexpression of peroxisome proliferator-activated receptor gamma have impaired repolarization and spontaneous fatal ventricular arrhythmias Circulation 124 2011 2812 2821
18. L. Ferreira, E. Teixeira-de-Lemos, and F. Pinto Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat) Mediators Inflamm 2010 2010 592760
19. L. Liu, J. Liu, and W.T. Wong Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism Hypertension 60 2012 833 841
20. 2 + exchanger inhibitor on pulmonary vein electrical activity and ouabain-induced arrhythmogenicity Cardiovasc Res 70 2006 497 508
21. T.I. Lee, Y.H. Kao, Y.C. Chen, N.H. Pan, and Y.J. Chen Oxidative stress and inflammation modulate peroxisome proliferator-activated receptors with regional discrepancy in diabetic heart Eur J Clin Invest 40 2010 692 699
22. K. Chinda, S. Palee, S. Surinkaew, M. Phornphutkul, S. Chattipakorn, and N. Chattipakorn Cardioprotective effect of dipeptidyl peptidase-4 inhibitor during ischemia-reperfusion injury Int J Cardiol 167 2013 451 457
23. N. Gomez, K. Touihri, and V. Matheeussen Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure Eur J Heart Fail 14 2012 14 21
24. P.A. Read, F.Z. Khan, P.M. Heck, S.P. Hoole, and D.P. Dutka DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease Circ Cardiovasc Imaging 3 2010 195 201
25. B.P. Pacheco, R.O. Crajoinas, and G.K. Couto Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats J Hypertens 29 2011 520 528
26. S. Vasdev, V.D. Gill, and P.K. Singal Modulation of oxidative stress-induced changes in hypertension and atherosclerosis by antioxidants Exp Clin Cardiol 11 2006 206 216
27. S. Vasdev, V. Gill, and P. Singal Role of advanced glycation end products in hypertension and atherosclerosis: therapeutic implications Cell Biochem Biophys 49 2007 48 63
28. A.R. Brasier, A. Recinos III, and M.S. Eledrisi Vascular inflammation and the renin-angiotensin system Arterioscler Thromb Vasc Biol 22 2002 1257 1266
29. C. Savoia, and E.L. Schiffrin Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions Clin Sci (Lond) 112 2007 375 384
30. J. Matsubara, S. Sugiyama, and K. Sugamura A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice J Am Coll Cardiol 59 2012 265 276
31. N.N. Ta, C.A. Schuyler, Y. Li, M.F. Lopes-Virella, and Y. Huang DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice J Cardiovasc Pharmacol 58 2011 157 166
32. B.C. Berk, K. Fujiwara, and S. Lehoux ECM remodeling in hypertensive heart disease J Clin Invest 117 2007 568 575
33. Y.H. Yeh, R. Wakili, and X.Y. Qi Calcium-handling abnormalities underlying atrial arrhythmogenesis and contractile dysfunction in dogs with congestive heart failure Circ Arrhythm Electrophysiol 1 2008 93 102
34. 2 + cycling and new therapeutic approaches for heart failure Circulation 121 2010 822 830
35. A. Planavila, J.C. Laguna, and M. Vazquez-Carrera Atorvastatin improves peroxisome proliferator-activated receptor signaling in cardiac hypertrophy by preventing nuclear factor-kappa B activation Biochim Biophys Acta 1687 2005 76 83
36. T.I. Lee, Y.H. Kao, Y.C. Chen, and Y.J. Chen Proinflammatory cytokine and ligands modulate cardiac peroxisome proliferator-activated receptors Eur J Clin Invest 39 2009 23 30